[1]
Raskin N.H.: Migraine: clinical aspects. [w:] Headache. 2d ed., Churchill
Livingstone, New York 1988.
[2]
Dilling-Ostrowska E. (red.): Zespoły bólowe w neurologii dziecięcej.
Wydawnictwo Lekarskie PZWL, Warszawa 2005.
[3]
Hamalainen ML.: Migraine in children. Guidelines for treatment. CNS
Drugs 1998; 10: 105–117.
[4]
Lipton R.B., Silberstein S.D., Stewart W.F.: An update on the epidemiology
of migraine. Headache 1994; 34: 319–328.
[5]
Mortimer M.J., Kay J., Jaron A.: Epidemiology of headache and
childhood migraine in a urban general practice using ad hoc, Vahkquist
and IHS criteria. Dev Med. Child Neurol 1992; 34: 1095–1101.
[6]
Mortimer M.J., Kay J., Jaron A.: Childhood migraine in general practice:
clinical features and characteristics. Cephalalgia 1992; 12: 238–243.
[7]
Stępień A.: Migrena i jej postacie kliniczne. Wydawnictwo Termedia,
Poznań 2009.
[8]
Lance J.W., Goadsby J.P.: Bóle głowy. Patofizjologia i leczenie.
Wydawnictwo D.W. Publishing Co. – Poland, Szczecin 1999.
[9]
Silberstein S.D.: Practice Parameter: evidence-based guidelines for
migraine headache (an evidence-based review). Neurology 2000; 55:
754–762.
[10]
Hershey A.D.: Current approaches to the diagnosis and management of
paediatric migraine. Lancet Neurol 2010; 9: 190–204.
[11]
Cuvellier J.C., Fily A., Joriot S., Cuisset J.M., Vallee L.: French general
practicioners’ management of children’s migraine headache. Headache
2007; 47: 1282–1292.
[12]
Boćkowski L., Sobaniec W., Śmigielska-Kuzia J., Kułak W.: Leczenie
migrenowych bólów głowy u dzieci. Klin Pediatr 2010; 18: 10–13.
[13]
Boćkowski L., Sobaniec W.: Zastosowanie topiramatu w leczeniu
profilaktycznym bólów głowy. [w:] Sobaniec W. (red.) Topiramat teoria
i praktyka. Wydawnictwo Medyczne Termedia, Poznań 2009; 55–66.
[14]
Boćkowski L.: Znaczenie czynników żywieniowych w migrenowych
bólach głowy. [w:] Zgorzalewicz-Stachowiak M. (red.) Problemy
diagnostyczne i terapeutyczne w bólach głowy u dzieci i młodzieży.
Wydawnictwo BiFolium , Lublin 2009; 95–108.
[15]
Geraud G., Lanteri-Minet M., Lucas C., Valace D.: French society for
the study of migraine headache (SFEMC). French guidelines for the
diagnosis and management of migraine in adults and children. Clinical
Therapy 2004; 26: 1305–1318.
[16]
Dowson A.J., Lipscombe S., Sender J., Rees T., Watson D.: MIPCA
Migraine Guideline Development Group. Migraine in Primary Care
Advisors. New guidelines for the management of migraine in primary
care. Current Medical Research and Opinion 2002; 18: 414–439.
[17]
Dilling-Ostrowska E., Koniecza S., Lubinska-Wykrzykowska L. et al.:
Obraz kliniczny migreny u dzieci w zależności od wieku. Neurol Neurochir
Pol 1999; 33, supl 5: 23–35.
[18]
Międzynarodowa Klasyfikacja Bólów Głowy, wydanie drugie. Neurol
Neurochir Pol 2006; 40, supl 1: 1–37.
[19]
Lewis D., Ashwal S, Hershey A. et al.: Practice Parameter:
Pharmacological treatment of migraine headache In children and
adolescents. Report of the American Academy of Neurology Quality
standards Subcomitee and the Practice Comitee of the Child Neurology
Society. Neurology 2004; 63: 2215–2244.
[20]
Evers S., Afra J., Frese A. et al.: EFNS guideline on the drug treatment of
migraine – revised report of an EFNS task force. Eur J Neurol 2009; 16:
968–981.
[21]
Hamalainen M.L., Hoppu K., Valkeila E. et al.: Ibuprophen or
acetaminophen for the acute treatment of migraine in children: a doubleblind,
randomized, placebo controlled, crossover study. Neurology 1997;
48: 102–107.
[22]
Lewis D.W., Kellstein D., Burke B. et al.: Children’s ibuprofen suspension
for the acute treatment of pediatric migraine headache. Headache 2002;
42: 780–786.
[23]
Doenicke A., Brand J., Perrin V.L.: Possible benefit of GR43175 a
novel5HT1 receptor agonist for the acute treatment of severe migraine.
Lancet 1988; 1: 1309–1311.
[24]
Üeberall M.A.: Intranasal sumatriptan for the acute treatment of migraine
treatment in children. Neurology 1999; 52: 1507–1510.
[25]
Winner P., Rothner A.A., Saper J. et al.: A randomized, double-blind,
placebo controlled study of sumatriptan nasal spray in the treatment of
acute migraine in adolescents. Pediatrics 2000; 106: 989–997.
[26]
Ahonen K., Hamalainen M.L., Rantala H. et al.: Nasal sumatriptan is
effective in the treatment of migraine attacks in children. Neurology
2004; 62: 883–887.
[27]
McDonald J.T.: Treatment of juvenile migraine with subcutaneous
sumatriptan. Headache 1994; 34: 581–582.
[28]
Linder S.L.: Subcutaneous sumatriptan in the clinical setting: The first
50 consecutive patients with acute migraine in the pediatric neurology
office practice. Headache 1996; 36: 419–422.
[29]
Winner P., Lewis D., Visser W.H. et al.: Rizatriptan 5mg for the acute
treatment of migraine in adolescents: a randomized, double-blind,
placebo-controlled study. Headache 2002; 42: 49–55.
[30]
Linder S.L., Dowson A.J.: Zolmitriptan provides effective migraine relief
in adolescents. Int J Clin Pract 2000; 54: 466–469.
[31]
Solomon G.D., Cady R.K., Klapper J.A. et al.: Clinical efficacy and
tolerability of 2,5 mg zolmitriptan for the acute treatment of migraine.
Neurology 1997; 49: 1219–1225.
[32]
Tepper S.J., Donnan G.A., Dowson A.J. et al.: A long-term study to
maximize relief with zolmitriptan. Curr Med Res Opin 1999; 15: 254–271.
[33]
Evers S., Rahmann A., Kraemer C. et al.: Treatment of childhood migraine
attacks with oral zolmitriptan and ibuprofen. Neurology 2006; 67: 497–
499.
[34]
Lewis D.W., Winner P., Hershey A.D. et al.: Adolescent Migraine Steering
Commitee: Efficacy of zolmitriptan nasal spray In adolescent migraine.
Pediatrics 2007; 120: 390–396.
[35]
Ahonen K., Hamalainen M.L., Eerola M. et al.: a randomized trial of
rizatriptan In migraine attacks In children. Neurology 2006; 67: 1135–
1140.
[36]
Stępień A.: Bóle głowy. Diagnostyka i leczenie. Wydanie I. Wydawnictwo
Czelej, Lublin, 2004.
[37]
Hamalainen M.L., Hoppu K., Santavuori P.V.: Oral dihydroergotamine for
therapy resistant migraine attacks in children. Pediatr Neurol 1997; 16:
114–117.
[38]
Kabbouche M.A., Linder S.L.: Management of migraine In children and
adolescents In the emergency department and inpatient setting. Curr
Pain Headache Rep 2005, 9: 363–367.
[39]
Kabbouche M.A., Powers S.W., Segers A., et al.: Inpatient treatment of
status migraine with duhydroergotamine in children and adolescents.
Headache 2009, 49: 106–109.
[40]
Winner P., Powers S.W., Kabbouche M.A., Hershey A.D. Diagnosing and
managing headache In children. Curr Treat Options Neurol 2007, 9: 3–13.
[41]
Walker D.M., Teach S.J.: Emergency department treatment of primary
headaches In children and adolescents. Curr Opin Pediatr 2008, 20:
248–254.
[42]
Brousseau D.C., Duffy S.J., Anderson A.C., Linakis A.G.: Treatment
of pediatric migraine headaches: a randomised double-blind trial of
prochlorperazine versus ketorolac. Ann Emerg Med 2004, 43: 256–262.
[43]
Gruppo L.Q. Jr. Intravenous Zofran for headache. J Emerg Med 2006; 31:
228–229.